# Literature Search Strategy Template

**ç”¨é€”**: ç³»ç»ŸåŒ–è®°å½•æ–‡çŒ®æ£€ç´¢è¿‡ç¨‹ï¼Œç¡®ä¿å¯é‡å¤æ€§å’Œé€æ˜åº¦
**é€‚ç”¨åœºæ™¯**: æ‰€æœ‰å¾ªè¯åŒ»å­¦ç ”ç©¶ã€ç³»ç»Ÿç»¼è¿°ã€Meta-analysis

---

## ğŸ” Literature Search Strategy

### 1. Research Question (PICO Framework)

| Element | Details |
|---------|---------|
| **P** (Population) | [ç›®æ ‡æ‚£è€…ç¾¤ä½“] |
| **I** (Intervention) | [å¹²é¢„æªæ–½/æš´éœ²å› ç´ ] |
| **C** (Comparison) | [å¯¹ç…§/æ¯”è¾ƒæªæ–½] |
| **O** (Outcome) | [å…³æ³¨ç»“å±€æŒ‡æ ‡] |
| **Study Design** | [æœŸæœ›ç ”ç©¶ç±»å‹ï¼šRCT / Observational / All] |
| **Time Frame** | [æ–‡çŒ®æ—¶é—´èŒƒå›´ï¼šå¦‚ 2015-2025] |

**Example**:
```
P: HER2é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…ï¼Œæ—¢å¾€æ¥å—è¿‡æ›²å¦¥ç å•æŠ—æ²»ç–—
I: Trastuzumab deruxtecan (T-DXd)
C: å…¶ä»–HER2é¶å‘æ²»ç–—ï¼ˆT-DM1, Tucatinibç­‰ï¼‰
O: ä¸»è¦å…³æ³¨ PFS, OS, ORRï¼›æ¬¡è¦å…³æ³¨ CNSç–—æ•ˆ, å®‰å…¨æ€§
Study Design: ä¼˜å…ˆRCTï¼Œæ¥å—é«˜è´¨é‡å•è‡‚ç ”ç©¶
Time Frame: 2018-2025ï¼ˆT-DXdé¦–æ¬¡æŠ¥é“è‡³ä»Šï¼‰
```

---

### 2. Search Databases & Dates

| Database | Search Date | Date Range | Results |
|----------|-------------|------------|---------|
| PubMed | YYYY-MM-DD | èµ·å§‹-ç»ˆæ­¢ | nç¯‡ |
| Cochrane Library | YYYY-MM-DD | èµ·å§‹-ç»ˆæ­¢ | nç¯‡ |
| Embase | YYYY-MM-DD | èµ·å§‹-ç»ˆæ­¢ | nç¯‡ |
| ClinicalTrials.gov | YYYY-MM-DD | All | né¡¹è¯•éªŒ |
| ASCO/ESMO Abstracts | YYYY-MM-DD | æœ€è¿‘2å¹´ | nç¯‡æ‘˜è¦ |

**Example**:
```
PubMed         | 2025-12-07 | 2018-2025 | 156
Cochrane       | 2025-12-07 | All       | 12
Embase         | 2025-12-07 | 2018-2025 | 234
ClinicalTrials | 2025-12-07 | All       | 23
ASCO/ESMO      | 2025-12-07 | 2024-2025 | 18
```

---

### 3. Search Strategy (Detailed)

#### 3.1 PubMed Search Strategy

**Search Date**: [YYYY-MM-DD]
**Filters Applied**: [è¯­è¨€/æ–‡ç« ç±»å‹/æ—¶é—´èŒƒå›´]

```
#1  "Breast Neoplasms"[Mesh] OR "breast cancer"[tiab] OR "breast carcinoma"[tiab]
#2  "Receptor, ErbB-2"[Mesh] OR "HER2"[tiab] OR "ERBB2"[tiab] OR "HER2-positive"[tiab]
#3  #1 AND #2
#4  "trastuzumab deruxtecan"[tiab] OR "T-DXd"[tiab] OR "DS-8201"[tiab] OR "Enhertu"[tiab]
#5  #3 AND #4
#6  "Neoplasm Metastasis"[Mesh] OR "metastatic"[tiab] OR "advanced"[tiab]
#7  #5 AND #6
#8  #7 AND ("2018/01/01"[PDAT] : "2025/12/07"[PDAT])
#9  #8 AND (English[lang] OR Chinese[lang])
#10 #9 AND (Clinical Trial[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp])

FINAL SEARCH: #10
Results: 156 articles
```

**Search String (å¤åˆ¶ç‰ˆ)**:
```
("Breast Neoplasms"[Mesh] OR "breast cancer"[tiab]) AND
("Receptor, ErbB-2"[Mesh] OR "HER2"[tiab] OR "HER2-positive"[tiab]) AND
("trastuzumab deruxtecan"[tiab] OR "T-DXd"[tiab] OR "DS-8201"[tiab] OR "Enhertu"[tiab]) AND
("Neoplasm Metastasis"[Mesh] OR "metastatic"[tiab]) AND
("2018/01/01"[PDAT] : "2025/12/07"[PDAT]) AND
(English[lang] OR Chinese[lang])
```

#### 3.2 Embase Search Strategy

**Search Date**: [YYYY-MM-DD]

```
#1  'breast cancer'/exp OR 'breast cancer':ab,ti
#2  'erb b2 receptor'/exp OR 'her2':ab,ti OR 'her2 positive':ab,ti
#3  #1 AND #2
#4  'trastuzumab deruxtecan'/exp OR 'trastuzumab deruxtecan':ab,ti OR 't dxd':ab,ti OR 'ds 8201':ab,ti
#5  #3 AND #4
#6  'metastasis'/exp OR 'metastatic':ab,ti OR 'advanced':ab,ti
#7  #5 AND #6
#8  #7 AND [2018-2025]/py
#9  #8 AND ([english]/lim OR [chinese]/lim)
#10 #9 AND ([article]/lim OR [review]/lim OR [randomized controlled trial]/lim)

FINAL SEARCH: #10
Results: 234 articles
```

#### 3.3 Cochrane Library Search Strategy

```
#1  MeSH descriptor: [Breast Neoplasms] explode all trees
#2  (breast cancer):ti,ab,kw OR (breast carcinoma):ti,ab,kw
#3  #1 OR #2
#4  MeSH descriptor: [Receptor, ErbB-2] explode all trees
#5  (HER2 OR ERBB2 OR HER2-positive):ti,ab,kw
#6  #4 OR #5
#7  #3 AND #6
#8  (trastuzumab deruxtecan OR T-DXd OR DS-8201 OR Enhertu):ti,ab,kw
#9  #7 AND #8
#10 (metastatic OR advanced):ti,ab,kw
#11 #9 AND #10 with Cochrane Library publication date Between 2018 and 2025

Results: 12 reviews
```

#### 3.4 ClinicalTrials.gov Search Strategy

**Search Interface**: Advanced Search

**Condition**: `Breast Cancer AND HER2-positive`
**Intervention**: `trastuzumab deruxtecan OR T-DXd OR DS-8201`
**Study Type**: `Interventional Studies (Clinical Trials)`
**Study Results**: `All Studies`
**Study Start**: `From 01/01/2018 to 12/07/2025`

**Results**: 23 trials

**Key Trials Identified**:
- NCT03529110 (DESTINY-Breast03)
- NCT03248492 (DESTINY-Breast01)
- NCT03523585 (DESTINY-Breast02)

#### 3.5 Conference Abstracts Search

**ASCO Annual Meeting (2024-2025)**:
- Search Term: `HER2-positive breast cancer trastuzumab deruxtecan`
- Results: 12 abstracts

**ESMO Congress (2024-2025)**:
- Search Term: `HER2+ breast cancer T-DXd`
- Results: 6 abstracts

---

### 4. Inclusion & Exclusion Criteria

#### Inclusion Criteria
- [ ] **Population**: HER2é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…
- [ ] **Intervention**: æ¶‰åŠT-DXdæ²»ç–—ï¼ˆä»»ä½•çº¿æ•°ï¼‰
- [ ] **Comparator**: æœ‰å¯¹ç…§ç»„æˆ–å†å²å¯¹ç…§
- [ ] **Outcomes**: æŠ¥å‘Šè‡³å°‘ä¸€é¡¹å…³é”®ç–—æ•ˆæŒ‡æ ‡ï¼ˆPFS/OS/ORRï¼‰
- [ ] **Study Design**: RCTã€å•è‡‚IIæœŸä¸´åºŠè¯•éªŒã€å¤§å‹é˜Ÿåˆ—ç ”ç©¶(Nâ‰¥50)
- [ ] **Language**: è‹±æ–‡æˆ–ä¸­æ–‡
- [ ] **Publication Type**: å…¨æ–‡å‘è¡¨æˆ–é‡è¦ä¼šè®®æ‘˜è¦

#### Exclusion Criteria
- [ ] **Population**: ä»…åŒ…å«HER2é˜´æ€§æ‚£è€…
- [ ] **Study Design**: Case reports (N<10), ç»¼è¿°/ç¤¾è®ºï¼ˆéç³»ç»Ÿç»¼è¿°ï¼‰
- [ ] **Outcomes**: ä»…æŠ¥å‘Šè¯ä»£åŠ¨åŠ›å­¦æ•°æ®ï¼Œæ— ä¸´åºŠç–—æ•ˆ
- [ ] **Duplication**: é‡å¤å‘è¡¨ï¼ˆä¿ç•™æœ€æ–°/æœ€å®Œæ•´ç‰ˆæœ¬ï¼‰
- [ ] **Quality**: æ˜æ˜¾æ–¹æ³•å­¦ç¼ºé™·çš„ç ”ç©¶

---

### 5. Screening Process

#### Stage 1: Title & Abstract Screening

| Source | Initial Results | After Title/Abstract Screening | Excluded | Exclusion Reasons |
|--------|-----------------|-------------------------------|----------|-------------------|
| PubMed | 156 | 45 | 111 | é‡å¤(32), æ— å…³äººç¾¤(45), Case reports(18), ç»¼è¿°(16) |
| Embase | 234 | 38 | 196 | ä¸PubMedé‡å¤(150), å…¶ä»–åŒä¸Š |
| Cochrane | 12 | 8 | 4 | ç³»ç»Ÿç»¼è¿°ï¼ˆçº³å…¥ä½†å•ç‹¬åˆ†æï¼‰ |
| ClinicalTrials | 23 | 15 | 8 | å·²ç»ˆæ­¢(3), ä»…IæœŸ(5) |
| Conferences | 18 | 6 | 12 | æ— æ–°æ•°æ®(å·²æ­£å¼å‘è¡¨) |
| **Total** | **443** | **112** | **331** | - |

**å»é‡å**: 85ç¯‡ç‹¬ç«‹ç ”ç©¶

#### Stage 2: Full-Text Screening

| Screening Result | Number | Key Studies |
|------------------|--------|-------------|
| **Included** | 12 | DESTINY-Breast01/02/03, å…¶ä»– |
| **Excluded** | 73 | è¯¦è§ä¸‹è¡¨ |

**Exclusion Reasons (Full-Text)**:

| Reason | Count | Examples |
|--------|-------|----------|
| æ— å…³ç»“å±€æŒ‡æ ‡ | 15 | ä»…æŠ¥å‘Šç”Ÿç‰©æ ‡å¿—ç‰©ï¼Œæ— ä¸´åºŠç»“å±€ |
| æ ·æœ¬é‡è¿‡å°(N<20) | 8 | å•ä¸­å¿ƒç»éªŒ |
| ç ”ç©¶è®¾è®¡ä¸ç¬¦ | 12 | å›é¡¾æ€§ç—…ä¾‹å¯¹ç…§ï¼Œè´¨é‡ä½ |
| æ•°æ®ä¸å®Œæ•´ | 18 | ä¼šè®®æ‘˜è¦ï¼Œæ•°æ®æœªæˆç†Ÿ |
| é‡å¤æŠ¥é“ | 20 | åŒä¸€ç ”ç©¶çš„ä¸åŒæ—¶é—´ç‚¹æ›´æ–°ï¼ˆä¿ç•™æœ€æ–°ï¼‰ |

---

### 6. Final Included Studies

| Study ID | First Author | Year | Design | Population | N | Key Findings | Evidence Level |
|----------|--------------|------|--------|------------|---|--------------|----------------|
| 1 | CortÃ©s J | 2022 | RCT Phase III | HER2+ mBC, 2L | 524 | T-DXd vs T-DM1: mPFS 28.8m vs 6.8m (HR 0.33) | Level 1 |
| 2 | Modi S | 2020 | Single-arm Phase II | HER2+ mBC, 3L+ | 184 | ORR 60.9%, mPFS 16.4m | Level 2 |
| 3 | ... | ... | ... | ... | ... | ... | ... |

**Total Included**: 12 studies
- RCTs: 3
- Single-arm trials: 6
- Observational studies: 3

---

### 7. Search Limitations & Biases

#### Acknowledged Limitations
- âœ… **Publication Bias**: æœªç³»ç»Ÿæ£€ç´¢ç°è‰²æ–‡çŒ®ï¼ˆå­¦ä½è®ºæ–‡ã€å†…éƒ¨æŠ¥å‘Šï¼‰
- âœ… **Language Bias**: ä»…çº³å…¥è‹±æ–‡å’Œä¸­æ–‡æ–‡çŒ®ï¼Œå¯èƒ½é—æ¼å…¶ä»–è¯­è¨€é‡è¦ç ”ç©¶
- âœ… **Time Lag**: æœ€æ–°ç ”ç©¶å¯èƒ½æœªè¢«ç´¢å¼•ï¼ˆæ£€ç´¢æ—¶é—´ï¼š2025-12-07ï¼‰
- âœ… **Database Coverage**: æœªæ£€ç´¢ä¸­æ–‡æ•°æ®åº“ï¼ˆä¸‡æ–¹ã€çŸ¥ç½‘ï¼‰

#### Mitigation Strategies
- æ£€ç´¢äº†ä¸»è¦ä¼šè®®æ‘˜è¦ï¼ˆASCO, ESMOï¼‰ä»¥çº³å…¥æœ€æ–°æ•°æ®
- æ‰‹å·¥æ£€ç´¢äº†çº³å…¥ç ”ç©¶çš„å‚è€ƒæ–‡çŒ®ï¼ˆsnowballingï¼‰
- å’¨è¯¢äº†ä¸´åºŠä¸“å®¶ï¼Œè¡¥å……é—æ¼çš„å…³é”®ç ”ç©¶

---

### 8. Supplementary Search Methods

#### Hand Searchï¼ˆæ‰‹å·¥æ£€ç´¢ï¼‰
- **Key Journals**:
  - New England Journal of Medicine
  - The Lancet Oncology
  - Journal of Clinical Oncology
  - Reviewed issues: 2020-2025

- **Results**: 2 additional studies identified

#### Citation Trackingï¼ˆå¼•æ–‡è¿½è¸ªï¼‰
- **Forward citation**: Google Scholarè·Ÿè¸ªDESTINY-Breast01çš„å¼•ç”¨ï¼ˆ524ç¯‡å¼•ç”¨ä¸­ç­›é€‰ï¼‰
- **Backward citation**: æ£€ç´¢çº³å…¥ç ”ç©¶çš„å‚è€ƒæ–‡çŒ®

- **Results**: 3 additional relevant studies

#### Expert Consultationï¼ˆä¸“å®¶å’¨è¯¢ï¼‰
- **Experts**: 2ä½ä¹³è…ºè‚¿ç˜¤ä¸“å®¶
- **Method**: æä¾›åˆæ­¥çº³å…¥ç ”ç©¶åˆ—è¡¨ï¼Œè¯¢é—®æ˜¯å¦é—æ¼é‡è¦ç ”ç©¶

- **Results**: ç¡®è®¤æœªé—æ¼å…³é”®ç ”ç©¶

---

### 9. Search Update Plan

**Initial Search Date**: 2025-12-07

**Planned Updates**:
- æ¯6ä¸ªæœˆæ›´æ–°ä¸€æ¬¡ï¼ˆä¸‹æ¬¡ï¼š2026-06-07ï¼‰
- é‡å¤§ä¸´åºŠè¯•éªŒç»“æœå…¬å¸ƒæ—¶ç«‹å³æ›´æ–°
- ä¸´åºŠæŒ‡å—æ›´æ–°æ—¶å¤æ ¸è¯æ®

**Update Alert Settings**:
- PubMed Auto-Alert: è®¾ç½®å…³é”®è¯è‡ªåŠ¨æé†’
- ClinicalTrials.gov: å…³æ³¨DESTINYç³»åˆ—è¯•éªŒè¿›å±•

---

## ğŸ“‹ PRISMA Flow Diagramï¼ˆå»ºè®®é…å›¾ï¼‰

```
                     Records identified through database searching
                                    (n = 443)
                                       â†“
                  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                  â”‚  Records after duplicates removed    â”‚
                  â”‚           (n = 85)                   â”‚
                  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                       â†“
                  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                  â”‚  Records screened                    â”‚
                  â”‚  (Title/Abstract)                    â”‚
                  â”‚           (n = 85)                   â”‚
                  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                       â†“
                              Records excluded (n = 0)
                  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                  â”‚  Full-text articles assessed         â”‚
                  â”‚  for eligibility                     â”‚
                  â”‚           (n = 85)                   â”‚
                  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                       â†“
                     Full-text excluded (n = 73)
                     Reasons:
                     - æ— å…³ç»“å±€: 15
                     - æ ·æœ¬é‡å°: 8
                     - è®¾è®¡ä¸ç¬¦: 12
                     - æ•°æ®ä¸å…¨: 18
                     - é‡å¤æŠ¥é“: 20
                  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                  â”‚  Studies included in                 â”‚
                  â”‚  qualitative synthesis               â”‚
                  â”‚           (n = 12)                   â”‚
                  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                       â†“
                  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                  â”‚  Studies included in                 â”‚
                  â”‚  quantitative synthesis              â”‚
                  â”‚  (meta-analysis)                     â”‚
                  â”‚           (n = 3 RCTs)               â”‚
                  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ” Search Quality Checklist

å®Œæˆæ£€ç´¢åï¼Œç¡®è®¤ä»¥ä¸‹è¦ç‚¹ï¼š

- [ ] **PICOæ˜ç¡®**: ç ”ç©¶é—®é¢˜ç”¨PICOæ¡†æ¶æ¸…æ™°å®šä¹‰
- [ ] **å¤šæ•°æ®åº“**: è‡³å°‘æ£€ç´¢3ä¸ªä¸»è¦æ•°æ®åº“
- [ ] **æ£€ç´¢å¼è®°å½•**: å®Œæ•´è®°å½•æ¯ä¸ªæ•°æ®åº“çš„æ£€ç´¢ç­–ç•¥ï¼ˆå¯é‡å¤ï¼‰
- [ ] **çº³æ’æ ‡å‡†**: æ˜ç¡®å®šä¹‰çº³å…¥å’Œæ’é™¤æ ‡å‡†
- [ ] **ç­›é€‰æµç¨‹**: è®°å½•æ¯ä¸€æ­¥ç­›é€‰çš„æ•°é‡å’ŒåŸå› 
- [ ] **åå€šè€ƒè™‘**: è¯†åˆ«å¹¶è¯´æ˜å¯èƒ½çš„åå€šæ¥æº
- [ ] **è¡¥å……æ£€ç´¢**: ä½¿ç”¨äº†è‡³å°‘ä¸€ç§è¡¥å……æ£€ç´¢æ–¹æ³•ï¼ˆæ‰‹æ£€/å¼•æ–‡/ä¸“å®¶ï¼‰
- [ ] **æ—¶æ•ˆæ€§**: æ˜ç¡®æ ‡æ³¨æ£€ç´¢æ—¥æœŸå’Œè®¡åˆ’æ›´æ–°æ—¶é—´

---

## ğŸ’¡ Common Search Terms by Specialty

### Oncologyï¼ˆè‚¿ç˜¤å­¦ï¼‰

**MeSH Terms**:
- Neoplasms / [specific cancer type]
- Antineoplastic Agents
- Molecular Targeted Therapy

**Keywords**:
- cancer, carcinoma, tumor, malignancy
- chemotherapy, immunotherapy, targeted therapy
- PFS, OS, ORR, DFS, pCR

### Cardiologyï¼ˆå¿ƒè¡€ç®¡ï¼‰

**MeSH Terms**:
- Cardiovascular Diseases
- Myocardial Infarction
- Heart Failure

**Keywords**:
- MACE, LVEF, NT-proBNP
- anticoagulation, antiplatelet

### Neurologyï¼ˆç¥ç»å­¦ï¼‰

**MeSH Terms**:
- Nervous System Diseases
- Stroke, Alzheimer Disease

**Keywords**:
- neuroprotection, cognitive function
- NIHSS, mRS, MMSE

---

## ğŸ¯ Tips for Efficient Search

**1. ä»å®½åˆ°çª„ï¼ˆFunnel Approachï¼‰**:
```
Step 1: å®½æ³›æ£€ç´¢ï¼ˆé«˜çµæ•åº¦ï¼‰ â†’ ç¡®ä¿ä¸é—æ¼
Step 2: ç²¾ç¡®ç­›é€‰ï¼ˆé«˜ç‰¹å¼‚åº¦ï¼‰ â†’ æ’é™¤æ— å…³
```

**2. å–„ç”¨MeSH Terms**:
```
é”™è¯¯: ä»…ç”¨å…³é”®è¯ "breast cancer"
æ­£ç¡®: "Breast Neoplasms"[Mesh] OR "breast cancer"[tiab]
ï¼ˆMeSHèƒ½è‡ªåŠ¨æ¶µç›–ä¸‹ä½è¯ï¼‰
```

**3. å¸ƒå°”è¿ç®—ç¬¦ä¼˜å…ˆçº§**:
```
é”™è¯¯: A OR B AND C ï¼ˆå¯èƒ½äº§ç”Ÿæ­§ä¹‰ï¼‰
æ­£ç¡®: (A OR B) AND C ï¼ˆæ˜ç¡®é€»è¾‘å…³ç³»ï¼‰
```

**4. æˆªè¯ç¬¦ä½¿ç”¨**:
```
PubMed: metasta* ï¼ˆåŒ¹é… metastasis, metastatic, metastasesï¼‰
Embase: $ ç¬¦å·
```

**5. é‚»è¿‘è¿ç®—ç¬¦**:
```
PubMed: "breast cancer"[tiab] ï¼ˆç²¾ç¡®çŸ­è¯­ï¼‰
Embase: 'breast cancer':ab,ti ï¼ˆæ ‡é¢˜æˆ–æ‘˜è¦ï¼‰
```

---

*Template Version: 1.0*
*Last Updated: 2025-12-07*
*Part of: Medical Research Analyst Skill - LiYe OS*
